nodes	percent_of_prediction	percent_of_DWPC	metapath
Metronidazole—CYP2C8—Sorafenib—liver cancer	0.179	0.426	CbGbCtD
Metronidazole—CYP2C9—Sorafenib—liver cancer	0.125	0.297	CbGbCtD
Metronidazole—CYP3A4—Sorafenib—liver cancer	0.0728	0.173	CbGbCtD
Metronidazole—CYP3A4—Doxorubicin—liver cancer	0.0442	0.105	CbGbCtD
Metronidazole—Hiccups—Doxorubicin—liver cancer	0.00129	0.00266	CcSEcCtD
Metronidazole—Vaginal inflammation—Doxorubicin—liver cancer	0.00129	0.00266	CcSEcCtD
Metronidazole—Anorexia—Sorafenib—liver cancer	0.00128	0.00264	CcSEcCtD
Metronidazole—Dermatitis contact—Doxorubicin—liver cancer	0.00127	0.00263	CcSEcCtD
Metronidazole—Eructation—Doxorubicin—liver cancer	0.00126	0.00261	CcSEcCtD
Metronidazole—Bladder pain—Epirubicin—liver cancer	0.00126	0.0026	CcSEcCtD
Metronidazole—Neoplasm—Epirubicin—liver cancer	0.00126	0.0026	CcSEcCtD
Metronidazole—Cystitis noninfective—Doxorubicin—liver cancer	0.00126	0.0026	CcSEcCtD
Metronidazole—Influenza like illness—Doxorubicin—liver cancer	0.00125	0.00258	CcSEcCtD
Metronidazole—Cystitis—Doxorubicin—liver cancer	0.00124	0.00257	CcSEcCtD
Metronidazole—Skin exfoliation—Doxorubicin—liver cancer	0.00123	0.00254	CcSEcCtD
Metronidazole—Candida infection—Doxorubicin—liver cancer	0.00123	0.00254	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00122	0.00253	CcSEcCtD
Metronidazole—Vaginal infection—Doxorubicin—liver cancer	0.00121	0.00251	CcSEcCtD
Metronidazole—Neuropathy—Doxorubicin—liver cancer	0.00121	0.0025	CcSEcCtD
Metronidazole—Aplastic anaemia—Doxorubicin—liver cancer	0.00121	0.0025	CcSEcCtD
Metronidazole—Dyspepsia—Sorafenib—liver cancer	0.00118	0.00244	CcSEcCtD
Metronidazole—Decreased appetite—Sorafenib—liver cancer	0.00117	0.00241	CcSEcCtD
Metronidazole—Thrombophlebitis—Epirubicin—liver cancer	0.00117	0.00241	CcSEcCtD
Metronidazole—Neoplasm—Doxorubicin—liver cancer	0.00116	0.0024	CcSEcCtD
Metronidazole—Bladder pain—Doxorubicin—liver cancer	0.00116	0.0024	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Sorafenib—liver cancer	0.00116	0.00239	CcSEcCtD
Metronidazole—Fatigue—Sorafenib—liver cancer	0.00116	0.00239	CcSEcCtD
Metronidazole—Photosensitivity—Epirubicin—liver cancer	0.00115	0.00237	CcSEcCtD
Metronidazole—Constipation—Sorafenib—liver cancer	0.00115	0.00237	CcSEcCtD
Metronidazole—Pain—Sorafenib—liver cancer	0.00115	0.00237	CcSEcCtD
Metronidazole—Hepatic failure—Epirubicin—liver cancer	0.00112	0.00232	CcSEcCtD
Metronidazole—Gastrointestinal pain—Sorafenib—liver cancer	0.0011	0.00227	CcSEcCtD
Metronidazole—Thrombophlebitis—Doxorubicin—liver cancer	0.00108	0.00223	CcSEcCtD
Metronidazole—Urticaria—Sorafenib—liver cancer	0.00107	0.0022	CcSEcCtD
Metronidazole—Photosensitivity—Doxorubicin—liver cancer	0.00106	0.0022	CcSEcCtD
Metronidazole—Body temperature increased—Sorafenib—liver cancer	0.00106	0.00219	CcSEcCtD
Metronidazole—Abdominal pain—Sorafenib—liver cancer	0.00106	0.00219	CcSEcCtD
Metronidazole—Dermatitis bullous—Epirubicin—liver cancer	0.00106	0.00218	CcSEcCtD
Metronidazole—Hepatic failure—Doxorubicin—liver cancer	0.00104	0.00215	CcSEcCtD
Metronidazole—CYP2C8—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00104	0.011	CbGpPWpGaD
Metronidazole—Osteoarthritis—Epirubicin—liver cancer	0.00101	0.00209	CcSEcCtD
Metronidazole—Diplopia—Epirubicin—liver cancer	0.00101	0.00209	CcSEcCtD
Metronidazole—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—liver cancer	0.000993	0.0105	CbGpPWpGaD
Metronidazole—Hypersensitivity—Sorafenib—liver cancer	0.000989	0.00204	CcSEcCtD
Metronidazole—CYP2C8—Xenobiotics—CYP1A1—liver cancer	0.000977	0.0104	CbGpPWpGaD
Metronidazole—Dermatitis bullous—Doxorubicin—liver cancer	0.000977	0.00202	CcSEcCtD
Metronidazole—Asthenia—Sorafenib—liver cancer	0.000963	0.00199	CcSEcCtD
Metronidazole—Pruritus—Sorafenib—liver cancer	0.00095	0.00196	CcSEcCtD
Metronidazole—Ataxia—Epirubicin—liver cancer	0.000949	0.00196	CcSEcCtD
Metronidazole—CYP2C8—Tamoxifen metabolism—CYP1A1—liver cancer	0.00094	0.00996	CbGpPWpGaD
Metronidazole—Osteoarthritis—Doxorubicin—liver cancer	0.000934	0.00193	CcSEcCtD
Metronidazole—Diplopia—Doxorubicin—liver cancer	0.000934	0.00193	CcSEcCtD
Metronidazole—Liver function test abnormal—Epirubicin—liver cancer	0.000932	0.00192	CcSEcCtD
Metronidazole—Dry skin—Epirubicin—liver cancer	0.000925	0.00191	CcSEcCtD
Metronidazole—Abdominal pain upper—Epirubicin—liver cancer	0.000922	0.0019	CcSEcCtD
Metronidazole—Diarrhoea—Sorafenib—liver cancer	0.000918	0.0019	CcSEcCtD
Metronidazole—Breast disorder—Epirubicin—liver cancer	0.000912	0.00188	CcSEcCtD
Metronidazole—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000909	0.00188	CcSEcCtD
Metronidazole—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.000904	0.00958	CbGpPWpGaD
Metronidazole—Nasopharyngitis—Epirubicin—liver cancer	0.000902	0.00186	CcSEcCtD
Metronidazole—Dizziness—Sorafenib—liver cancer	0.000888	0.00183	CcSEcCtD
Metronidazole—Abdominal distension—Epirubicin—liver cancer	0.000878	0.00181	CcSEcCtD
Metronidazole—Ataxia—Doxorubicin—liver cancer	0.000878	0.00181	CcSEcCtD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.000876	0.00929	CbGpPWpGaD
Metronidazole—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.000873	0.00925	CbGpPWpGaD
Metronidazole—Influenza—Epirubicin—liver cancer	0.000872	0.0018	CcSEcCtD
Metronidazole—Asthma—Epirubicin—liver cancer	0.000872	0.0018	CcSEcCtD
Metronidazole—Eosinophilia—Epirubicin—liver cancer	0.000864	0.00178	CcSEcCtD
Metronidazole—Liver function test abnormal—Doxorubicin—liver cancer	0.000862	0.00178	CcSEcCtD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.000862	0.00913	CbGpPWpGaD
Metronidazole—Dry skin—Doxorubicin—liver cancer	0.000856	0.00177	CcSEcCtD
Metronidazole—Pancreatitis—Epirubicin—liver cancer	0.000855	0.00177	CcSEcCtD
Metronidazole—Vomiting—Sorafenib—liver cancer	0.000853	0.00176	CcSEcCtD
Metronidazole—Abdominal pain upper—Doxorubicin—liver cancer	0.000853	0.00176	CcSEcCtD
Metronidazole—Rash—Sorafenib—liver cancer	0.000846	0.00175	CcSEcCtD
Metronidazole—Dermatitis—Sorafenib—liver cancer	0.000845	0.00175	CcSEcCtD
Metronidazole—Breast disorder—Doxorubicin—liver cancer	0.000844	0.00174	CcSEcCtD
Metronidazole—CYP2C9—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000844	0.00894	CbGpPWpGaD
Metronidazole—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000841	0.00174	CcSEcCtD
Metronidazole—Headache—Sorafenib—liver cancer	0.000841	0.00174	CcSEcCtD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.00084	0.0089	CbGpPWpGaD
Metronidazole—Bronchitis—Epirubicin—liver cancer	0.000839	0.00173	CcSEcCtD
Metronidazole—Nasopharyngitis—Doxorubicin—liver cancer	0.000835	0.00173	CcSEcCtD
Metronidazole—Pancytopenia—Epirubicin—liver cancer	0.000828	0.00171	CcSEcCtD
Metronidazole—Neutropenia—Epirubicin—liver cancer	0.000816	0.00169	CcSEcCtD
Metronidazole—Dysuria—Epirubicin—liver cancer	0.000816	0.00169	CcSEcCtD
Metronidazole—Abdominal distension—Doxorubicin—liver cancer	0.000812	0.00168	CcSEcCtD
Metronidazole—Upper respiratory tract infection—Epirubicin—liver cancer	0.000811	0.00167	CcSEcCtD
Metronidazole—Asthma—Doxorubicin—liver cancer	0.000807	0.00167	CcSEcCtD
Metronidazole—Influenza—Doxorubicin—liver cancer	0.000807	0.00167	CcSEcCtD
Metronidazole—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.000806	0.00854	CbGpPWpGaD
Metronidazole—Pollakiuria—Epirubicin—liver cancer	0.000806	0.00166	CcSEcCtD
Metronidazole—CYP2C8—Arachidonic acid metabolism—HPGDS—liver cancer	0.000802	0.00849	CbGpPWpGaD
Metronidazole—Eosinophilia—Doxorubicin—liver cancer	0.000799	0.00165	CcSEcCtD
Metronidazole—Nausea—Sorafenib—liver cancer	0.000797	0.00165	CcSEcCtD
Metronidazole—Photosensitivity reaction—Epirubicin—liver cancer	0.000796	0.00164	CcSEcCtD
Metronidazole—CYP2C9—Xenobiotics—CYP1A1—liver cancer	0.000795	0.00842	CbGpPWpGaD
Metronidazole—Pancreatitis—Doxorubicin—liver cancer	0.000791	0.00163	CcSEcCtD
Metronidazole—Infestation NOS—Epirubicin—liver cancer	0.000778	0.00161	CcSEcCtD
Metronidazole—Drowsiness—Epirubicin—liver cancer	0.000778	0.00161	CcSEcCtD
Metronidazole—Infestation—Epirubicin—liver cancer	0.000778	0.00161	CcSEcCtD
Metronidazole—Bronchitis—Doxorubicin—liver cancer	0.000776	0.0016	CcSEcCtD
Metronidazole—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000771	0.00159	CcSEcCtD
Metronidazole—Pancytopenia—Doxorubicin—liver cancer	0.000766	0.00158	CcSEcCtD
Metronidazole—CYP2C9—Tamoxifen metabolism—CYP1A1—liver cancer	0.000765	0.0081	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—UGDH—liver cancer	0.000764	0.0081	CbGpPWpGaD
Metronidazole—Neuropathy peripheral—Epirubicin—liver cancer	0.000762	0.00158	CcSEcCtD
Metronidazole—Jaundice—Epirubicin—liver cancer	0.000758	0.00157	CcSEcCtD
Metronidazole—Stomatitis—Epirubicin—liver cancer	0.000758	0.00157	CcSEcCtD
Metronidazole—Conjunctivitis—Epirubicin—liver cancer	0.000756	0.00156	CcSEcCtD
Metronidazole—Urinary tract infection—Epirubicin—liver cancer	0.000756	0.00156	CcSEcCtD
Metronidazole—Neutropenia—Doxorubicin—liver cancer	0.000755	0.00156	CcSEcCtD
Metronidazole—Dysuria—Doxorubicin—liver cancer	0.000755	0.00156	CcSEcCtD
Metronidazole—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00075	0.00155	CcSEcCtD
Metronidazole—Sweating—Epirubicin—liver cancer	0.000746	0.00154	CcSEcCtD
Metronidazole—Pollakiuria—Doxorubicin—liver cancer	0.000746	0.00154	CcSEcCtD
Metronidazole—Photosensitivity reaction—Doxorubicin—liver cancer	0.000737	0.00152	CcSEcCtD
Metronidazole—Hepatobiliary disease—Epirubicin—liver cancer	0.000736	0.00152	CcSEcCtD
Metronidazole—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.00073	0.00773	CbGpPWpGaD
Metronidazole—Sinusitis—Epirubicin—liver cancer	0.00073	0.00151	CcSEcCtD
Metronidazole—Agranulocytosis—Epirubicin—liver cancer	0.000726	0.0015	CcSEcCtD
Metronidazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000724	0.00767	CbGpPWpGaD
Metronidazole—Infestation NOS—Doxorubicin—liver cancer	0.00072	0.00149	CcSEcCtD
Metronidazole—Drowsiness—Doxorubicin—liver cancer	0.00072	0.00149	CcSEcCtD
Metronidazole—Infestation—Doxorubicin—liver cancer	0.00072	0.00149	CcSEcCtD
Metronidazole—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000713	0.00147	CcSEcCtD
Metronidazole—Neuropathy peripheral—Doxorubicin—liver cancer	0.000705	0.00146	CcSEcCtD
Metronidazole—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.000702	0.00744	CbGpPWpGaD
Metronidazole—Stomatitis—Doxorubicin—liver cancer	0.000701	0.00145	CcSEcCtD
Metronidazole—Jaundice—Doxorubicin—liver cancer	0.000701	0.00145	CcSEcCtD
Metronidazole—Rhinitis—Epirubicin—liver cancer	0.0007	0.00145	CcSEcCtD
Metronidazole—Conjunctivitis—Doxorubicin—liver cancer	0.000699	0.00145	CcSEcCtD
Metronidazole—Urinary tract infection—Doxorubicin—liver cancer	0.000699	0.00145	CcSEcCtD
Metronidazole—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.000698	0.0074	CbGpPWpGaD
Metronidazole—Hepatitis—Epirubicin—liver cancer	0.000698	0.00144	CcSEcCtD
Metronidazole—Hypoaesthesia—Epirubicin—liver cancer	0.000695	0.00144	CcSEcCtD
Metronidazole—Pharyngitis—Epirubicin—liver cancer	0.000693	0.00143	CcSEcCtD
Metronidazole—Sweating—Doxorubicin—liver cancer	0.00069	0.00143	CcSEcCtD
Metronidazole—Connective tissue disorder—Epirubicin—liver cancer	0.000686	0.00142	CcSEcCtD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000684	0.00725	CbGpPWpGaD
Metronidazole—Hepatobiliary disease—Doxorubicin—liver cancer	0.000681	0.00141	CcSEcCtD
Metronidazole—Sinusitis—Doxorubicin—liver cancer	0.000675	0.00139	CcSEcCtD
Metronidazole—Visual impairment—Epirubicin—liver cancer	0.000673	0.00139	CcSEcCtD
Metronidazole—Agranulocytosis—Doxorubicin—liver cancer	0.000672	0.00139	CcSEcCtD
Metronidazole—Erythema multiforme—Epirubicin—liver cancer	0.00066	0.00136	CcSEcCtD
Metronidazole—Eye disorder—Epirubicin—liver cancer	0.000652	0.00135	CcSEcCtD
Metronidazole—CYP2C9—Arachidonic acid metabolism—HPGDS—liver cancer	0.000652	0.00691	CbGpPWpGaD
Metronidazole—Tinnitus—Epirubicin—liver cancer	0.000651	0.00134	CcSEcCtD
Metronidazole—Cardiac disorder—Epirubicin—liver cancer	0.000648	0.00134	CcSEcCtD
Metronidazole—Flushing—Epirubicin—liver cancer	0.000648	0.00134	CcSEcCtD
Metronidazole—Rhinitis—Doxorubicin—liver cancer	0.000648	0.00134	CcSEcCtD
Metronidazole—Hepatitis—Doxorubicin—liver cancer	0.000646	0.00133	CcSEcCtD
Metronidazole—Hypoaesthesia—Doxorubicin—liver cancer	0.000643	0.00133	CcSEcCtD
Metronidazole—Pharyngitis—Doxorubicin—liver cancer	0.000641	0.00132	CcSEcCtD
Metronidazole—Connective tissue disorder—Doxorubicin—liver cancer	0.000635	0.00131	CcSEcCtD
Metronidazole—Angiopathy—Epirubicin—liver cancer	0.000633	0.00131	CcSEcCtD
Metronidazole—Immune system disorder—Epirubicin—liver cancer	0.000631	0.0013	CcSEcCtD
Metronidazole—Mediastinal disorder—Epirubicin—liver cancer	0.000629	0.0013	CcSEcCtD
Metronidazole—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.000627	0.00664	CbGpPWpGaD
Metronidazole—Visual impairment—Doxorubicin—liver cancer	0.000623	0.00129	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—UGDH—liver cancer	0.000622	0.00659	CbGpPWpGaD
Metronidazole—Mental disorder—Epirubicin—liver cancer	0.000612	0.00126	CcSEcCtD
Metronidazole—Erythema multiforme—Doxorubicin—liver cancer	0.000611	0.00126	CcSEcCtD
Metronidazole—Erythema—Epirubicin—liver cancer	0.000608	0.00126	CcSEcCtD
Metronidazole—Eye disorder—Doxorubicin—liver cancer	0.000604	0.00125	CcSEcCtD
Metronidazole—Tinnitus—Doxorubicin—liver cancer	0.000602	0.00124	CcSEcCtD
Metronidazole—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.000602	0.00638	CbGpPWpGaD
Metronidazole—CYP2C8—Arachidonic acid metabolism—GGT1—liver cancer	0.0006	0.00636	CbGpPWpGaD
Metronidazole—Flushing—Doxorubicin—liver cancer	0.0006	0.00124	CcSEcCtD
Metronidazole—Cardiac disorder—Doxorubicin—liver cancer	0.0006	0.00124	CcSEcCtD
Metronidazole—Flatulence—Epirubicin—liver cancer	0.000599	0.00124	CcSEcCtD
Metronidazole—Dysgeusia—Epirubicin—liver cancer	0.000595	0.00123	CcSEcCtD
Metronidazole—Back pain—Epirubicin—liver cancer	0.000588	0.00121	CcSEcCtD
Metronidazole—Angiopathy—Doxorubicin—liver cancer	0.000586	0.00121	CcSEcCtD
Metronidazole—Muscle spasms—Epirubicin—liver cancer	0.000584	0.00121	CcSEcCtD
Metronidazole—Immune system disorder—Doxorubicin—liver cancer	0.000583	0.00121	CcSEcCtD
Metronidazole—Mediastinal disorder—Doxorubicin—liver cancer	0.000582	0.0012	CcSEcCtD
Metronidazole—Vision blurred—Epirubicin—liver cancer	0.000573	0.00118	CcSEcCtD
Metronidazole—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.000571	0.00604	CbGpPWpGaD
Metronidazole—Mental disorder—Doxorubicin—liver cancer	0.000566	0.00117	CcSEcCtD
Metronidazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000565	0.00598	CbGpPWpGaD
Metronidazole—Erythema—Doxorubicin—liver cancer	0.000562	0.00116	CcSEcCtD
Metronidazole—CYP2C8—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000557	0.0059	CbGpPWpGaD
Metronidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000556	0.00589	CbGpPWpGaD
Metronidazole—Flatulence—Doxorubicin—liver cancer	0.000554	0.00114	CcSEcCtD
Metronidazole—Dysgeusia—Doxorubicin—liver cancer	0.000551	0.00114	CcSEcCtD
Metronidazole—Malaise—Epirubicin—liver cancer	0.000548	0.00113	CcSEcCtD
Metronidazole—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.000546	0.00579	CbGpPWpGaD
Metronidazole—Vertigo—Epirubicin—liver cancer	0.000546	0.00113	CcSEcCtD
Metronidazole—Syncope—Epirubicin—liver cancer	0.000545	0.00113	CcSEcCtD
Metronidazole—Leukopenia—Epirubicin—liver cancer	0.000544	0.00112	CcSEcCtD
Metronidazole—Back pain—Doxorubicin—liver cancer	0.000544	0.00112	CcSEcCtD
Metronidazole—Muscle spasms—Doxorubicin—liver cancer	0.000541	0.00112	CcSEcCtD
Metronidazole—Palpitations—Epirubicin—liver cancer	0.000537	0.00111	CcSEcCtD
Metronidazole—Loss of consciousness—Epirubicin—liver cancer	0.000534	0.0011	CcSEcCtD
Metronidazole—Vision blurred—Doxorubicin—liver cancer	0.00053	0.00109	CcSEcCtD
Metronidazole—Convulsion—Epirubicin—liver cancer	0.000527	0.00109	CcSEcCtD
Metronidazole—Hypertension—Epirubicin—liver cancer	0.000525	0.00108	CcSEcCtD
Metronidazole—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.000524	0.00556	CbGpPWpGaD
Metronidazole—Arthralgia—Epirubicin—liver cancer	0.000517	0.00107	CcSEcCtD
Metronidazole—Chest pain—Epirubicin—liver cancer	0.000517	0.00107	CcSEcCtD
Metronidazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000514	0.00106	CcSEcCtD
Metronidazole—Malaise—Doxorubicin—liver cancer	0.000507	0.00105	CcSEcCtD
Metronidazole—Dry mouth—Epirubicin—liver cancer	0.000506	0.00105	CcSEcCtD
Metronidazole—Vertigo—Doxorubicin—liver cancer	0.000505	0.00104	CcSEcCtD
Metronidazole—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.000504	0.00534	CbGpPWpGaD
Metronidazole—Syncope—Doxorubicin—liver cancer	0.000504	0.00104	CcSEcCtD
Metronidazole—Leukopenia—Doxorubicin—liver cancer	0.000503	0.00104	CcSEcCtD
Metronidazole—Confusional state—Epirubicin—liver cancer	0.0005	0.00103	CcSEcCtD
Metronidazole—Palpitations—Doxorubicin—liver cancer	0.000497	0.00103	CcSEcCtD
Metronidazole—Oedema—Epirubicin—liver cancer	0.000496	0.00102	CcSEcCtD
Metronidazole—Anaphylactic shock—Epirubicin—liver cancer	0.000496	0.00102	CcSEcCtD
Metronidazole—Loss of consciousness—Doxorubicin—liver cancer	0.000494	0.00102	CcSEcCtD
Metronidazole—Infection—Epirubicin—liver cancer	0.000493	0.00102	CcSEcCtD
Metronidazole—CYP2C9—Arachidonic acid metabolism—GGT1—liver cancer	0.000488	0.00517	CbGpPWpGaD
Metronidazole—Shock—Epirubicin—liver cancer	0.000488	0.00101	CcSEcCtD
Metronidazole—Convulsion—Doxorubicin—liver cancer	0.000487	0.00101	CcSEcCtD
Metronidazole—Nervous system disorder—Epirubicin—liver cancer	0.000486	0.001	CcSEcCtD
Metronidazole—Thrombocytopenia—Epirubicin—liver cancer	0.000486	0.001	CcSEcCtD
Metronidazole—Hypertension—Doxorubicin—liver cancer	0.000486	0.001	CcSEcCtD
Metronidazole—Skin disorder—Epirubicin—liver cancer	0.000482	0.000995	CcSEcCtD
Metronidazole—Hyperhidrosis—Epirubicin—liver cancer	0.00048	0.000991	CcSEcCtD
Metronidazole—Arthralgia—Doxorubicin—liver cancer	0.000479	0.000989	CcSEcCtD
Metronidazole—Chest pain—Doxorubicin—liver cancer	0.000479	0.000989	CcSEcCtD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000477	0.00506	CbGpPWpGaD
Metronidazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000476	0.00504	CbGpPWpGaD
Metronidazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000475	0.000982	CcSEcCtD
Metronidazole—Anorexia—Epirubicin—liver cancer	0.000473	0.000977	CcSEcCtD
Metronidazole—CYP2C8—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000469	0.00497	CbGpPWpGaD
Metronidazole—Dry mouth—Doxorubicin—liver cancer	0.000468	0.000967	CcSEcCtD
Metronidazole—Confusional state—Doxorubicin—liver cancer	0.000463	0.000956	CcSEcCtD
Metronidazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.00046	0.00487	CbGpPWpGaD
Metronidazole—Anaphylactic shock—Doxorubicin—liver cancer	0.000459	0.000948	CcSEcCtD
Metronidazole—Oedema—Doxorubicin—liver cancer	0.000459	0.000948	CcSEcCtD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000458	0.00485	CbGpPWpGaD
Metronidazole—Infection—Doxorubicin—liver cancer	0.000456	0.000942	CcSEcCtD
Metronidazole—CYP2C9—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000454	0.00481	CbGpPWpGaD
Metronidazole—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000452	0.000934	CcSEcCtD
Metronidazole—Shock—Doxorubicin—liver cancer	0.000452	0.000933	CcSEcCtD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000451	0.00478	CbGpPWpGaD
Metronidazole—Nervous system disorder—Doxorubicin—liver cancer	0.00045	0.00093	CcSEcCtD
Metronidazole—Thrombocytopenia—Doxorubicin—liver cancer	0.000449	0.000928	CcSEcCtD
Metronidazole—Insomnia—Epirubicin—liver cancer	0.000449	0.000927	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—NR1H4—liver cancer	0.000446	0.00473	CbGpPWpGaD
Metronidazole—Skin disorder—Doxorubicin—liver cancer	0.000446	0.000921	CcSEcCtD
Metronidazole—Paraesthesia—Epirubicin—liver cancer	0.000445	0.00092	CcSEcCtD
Metronidazole—Hyperhidrosis—Doxorubicin—liver cancer	0.000444	0.000917	CcSEcCtD
Metronidazole—Somnolence—Epirubicin—liver cancer	0.000441	0.000911	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—GSTA3—liver cancer	0.000439	0.00465	CbGpPWpGaD
Metronidazole—Anorexia—Doxorubicin—liver cancer	0.000437	0.000904	CcSEcCtD
Metronidazole—Dyspepsia—Epirubicin—liver cancer	0.000437	0.000902	CcSEcCtD
Metronidazole—CYP2C8—Metapathway biotransformation—GSTA3—liver cancer	0.000433	0.00459	CbGpPWpGaD
Metronidazole—Decreased appetite—Epirubicin—liver cancer	0.000431	0.000891	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Epirubicin—liver cancer	0.000428	0.000885	CcSEcCtD
Metronidazole—Fatigue—Epirubicin—liver cancer	0.000428	0.000884	CcSEcCtD
Metronidazole—Constipation—Epirubicin—liver cancer	0.000424	0.000876	CcSEcCtD
Metronidazole—Pain—Epirubicin—liver cancer	0.000424	0.000876	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000418	0.000864	CcSEcCtD
Metronidazole—Insomnia—Doxorubicin—liver cancer	0.000415	0.000858	CcSEcCtD
Metronidazole—Paraesthesia—Doxorubicin—liver cancer	0.000412	0.000851	CcSEcCtD
Metronidazole—CYP3A4—Biological oxidations—UGDH—liver cancer	0.00041	0.00435	CbGpPWpGaD
Metronidazole—Feeling abnormal—Epirubicin—liver cancer	0.000409	0.000844	CcSEcCtD
Metronidazole—Somnolence—Doxorubicin—liver cancer	0.000408	0.000843	CcSEcCtD
Metronidazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000406	0.0043	CbGpPWpGaD
Metronidazole—Gastrointestinal pain—Epirubicin—liver cancer	0.000406	0.000838	CcSEcCtD
Metronidazole—Dyspepsia—Doxorubicin—liver cancer	0.000404	0.000835	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—GSTA4—liver cancer	0.000401	0.00425	CbGpPWpGaD
Metronidazole—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.0004	0.00424	CbGpPWpGaD
Metronidazole—Decreased appetite—Doxorubicin—liver cancer	0.000399	0.000824	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000396	0.000819	CcSEcCtD
Metronidazole—CYP2C8—Metapathway biotransformation—GSTA4—liver cancer	0.000396	0.00419	CbGpPWpGaD
Metronidazole—Fatigue—Doxorubicin—liver cancer	0.000396	0.000818	CcSEcCtD
Metronidazole—Urticaria—Epirubicin—liver cancer	0.000394	0.000814	CcSEcCtD
Metronidazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000393	0.00417	CbGpPWpGaD
Metronidazole—Constipation—Doxorubicin—liver cancer	0.000392	0.000811	CcSEcCtD
Metronidazole—Pain—Doxorubicin—liver cancer	0.000392	0.000811	CcSEcCtD
Metronidazole—Body temperature increased—Epirubicin—liver cancer	0.000392	0.00081	CcSEcCtD
Metronidazole—Abdominal pain—Epirubicin—liver cancer	0.000392	0.00081	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—GSTA2—liver cancer	0.000391	0.00414	CbGpPWpGaD
Metronidazole—CYP2C9—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000382	0.00405	CbGpPWpGaD
Metronidazole—Feeling abnormal—Doxorubicin—liver cancer	0.000378	0.000781	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—GSTA1—liver cancer	0.000377	0.004	CbGpPWpGaD
Metronidazole—Gastrointestinal pain—Doxorubicin—liver cancer	0.000375	0.000775	CcSEcCtD
Metronidazole—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000375	0.00397	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—NAT2—liver cancer	0.000373	0.00395	CbGpPWpGaD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000373	0.00395	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—NAT2—liver cancer	0.000368	0.0039	CbGpPWpGaD
Metronidazole—Hypersensitivity—Epirubicin—liver cancer	0.000365	0.000755	CcSEcCtD
Metronidazole—Urticaria—Doxorubicin—liver cancer	0.000365	0.000753	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—NR1H4—liver cancer	0.000363	0.00385	CbGpPWpGaD
Metronidazole—Abdominal pain—Doxorubicin—liver cancer	0.000363	0.00075	CcSEcCtD
Metronidazole—Body temperature increased—Doxorubicin—liver cancer	0.000363	0.00075	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—GSTA3—liver cancer	0.000357	0.00378	CbGpPWpGaD
Metronidazole—Asthenia—Epirubicin—liver cancer	0.000356	0.000735	CcSEcCtD
Metronidazole—CYP2C9—Metapathway biotransformation—GSTA3—liver cancer	0.000352	0.00373	CbGpPWpGaD
Metronidazole—Pruritus—Epirubicin—liver cancer	0.000351	0.000725	CcSEcCtD
Metronidazole—Diarrhoea—Epirubicin—liver cancer	0.000339	0.000701	CcSEcCtD
Metronidazole—Hypersensitivity—Doxorubicin—liver cancer	0.000338	0.000699	CcSEcCtD
Metronidazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.00033	0.0035	CbGpPWpGaD
Metronidazole—Asthenia—Doxorubicin—liver cancer	0.000329	0.00068	CcSEcCtD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000329	0.00348	CbGpPWpGaD
Metronidazole—Dizziness—Epirubicin—liver cancer	0.000328	0.000678	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—GSTA4—liver cancer	0.000327	0.00346	CbGpPWpGaD
Metronidazole—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000326	0.00345	CbGpPWpGaD
Metronidazole—Pruritus—Doxorubicin—liver cancer	0.000325	0.000671	CcSEcCtD
Metronidazole—CYP2C9—Metapathway biotransformation—GSTA4—liver cancer	0.000322	0.00341	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—GSTA2—liver cancer	0.000318	0.00337	CbGpPWpGaD
Metronidazole—Vomiting—Epirubicin—liver cancer	0.000315	0.000652	CcSEcCtD
Metronidazole—Diarrhoea—Doxorubicin—liver cancer	0.000314	0.000649	CcSEcCtD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000314	0.00332	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—GPX3—liver cancer	0.000313	0.00332	CbGpPWpGaD
Metronidazole—Rash—Epirubicin—liver cancer	0.000313	0.000646	CcSEcCtD
Metronidazole—Dermatitis—Epirubicin—liver cancer	0.000312	0.000646	CcSEcCtD
Metronidazole—Headache—Epirubicin—liver cancer	0.000311	0.000642	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—GSTA1—liver cancer	0.000307	0.00325	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—NAT2—liver cancer	0.000304	0.00322	CbGpPWpGaD
Metronidazole—Dizziness—Doxorubicin—liver cancer	0.000303	0.000627	CcSEcCtD
Metronidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000303	0.00321	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—NAT2—liver cancer	0.0003	0.00317	CbGpPWpGaD
Metronidazole—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000299	0.00317	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—HPGDS—liver cancer	0.000298	0.00316	CbGpPWpGaD
Metronidazole—Nausea—Epirubicin—liver cancer	0.000295	0.000609	CcSEcCtD
Metronidazole—Vomiting—Doxorubicin—liver cancer	0.000292	0.000603	CcSEcCtD
Metronidazole—Rash—Doxorubicin—liver cancer	0.000289	0.000598	CcSEcCtD
Metronidazole—Dermatitis—Doxorubicin—liver cancer	0.000289	0.000597	CcSEcCtD
Metronidazole—Headache—Doxorubicin—liver cancer	0.000288	0.000594	CcSEcCtD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000276	0.00292	CbGpPWpGaD
Metronidazole—Nausea—Doxorubicin—liver cancer	0.000273	0.000563	CcSEcCtD
Metronidazole—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000269	0.00285	CbGpPWpGaD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000268	0.00284	CbGpPWpGaD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000259	0.00275	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—GPX3—liver cancer	0.000255	0.0027	CbGpPWpGaD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000246	0.0026	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—CYP2E1—liver cancer	0.000243	0.00258	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—HPGDS—liver cancer	0.000243	0.00257	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—CYP2E1—liver cancer	0.00024	0.00254	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.00024	0.00254	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000236	0.0025	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000232	0.00246	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000225	0.00238	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—GGT1—liver cancer	0.000223	0.00237	CbGpPWpGaD
Metronidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000218	0.00231	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000215	0.00228	CbGpPWpGaD
Metronidazole—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000215	0.00228	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000212	0.00225	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.00021	0.00222	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000203	0.00215	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—GSTP1—liver cancer	0.000201	0.00212	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—NAT2—liver cancer	0.0002	0.00212	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—CYP2E1—liver cancer	0.000198	0.0021	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—GSTP1—liver cancer	0.000198	0.0021	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000198	0.00209	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—CYP2E1—liver cancer	0.000195	0.00207	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—GSTM1—liver cancer	0.000184	0.00195	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—GSTM1—liver cancer	0.000182	0.00193	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—GGT1—liver cancer	0.000182	0.00193	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000178	0.00188	CbGpPWpGaD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000177	0.00187	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—CYP1A1—liver cancer	0.000175	0.00185	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—CYP1A1—liver cancer	0.000172	0.00183	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000171	0.00182	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000168	0.00178	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—GSTP1—liver cancer	0.000163	0.00173	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—GSTP1—liver cancer	0.000161	0.00171	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.00016	0.0017	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—GSTM1—liver cancer	0.00015	0.00159	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—GSTM1—liver cancer	0.000148	0.00157	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000145	0.00153	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—CYP1A1—liver cancer	0.000142	0.00151	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—CYP1A1—liver cancer	0.00014	0.00149	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.00014	0.00148	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000131	0.00139	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—UGDH—liver cancer	0.000131	0.00138	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000131	0.00138	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000129	0.00136	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—EPT1—liver cancer	0.000123	0.0013	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GGT1—liver cancer	0.00012	0.00127	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—TAT—liver cancer	0.000116	0.00123	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000115	0.00121	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000108	0.00114	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000107	0.00113	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—UGDH—liver cancer	0.000106	0.00113	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000106	0.00112	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—EPT1—liver cancer	0.0001	0.00106	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTM1—liver cancer	9.89e-05	0.00105	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	9.76e-05	0.00103	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—TAT—liver cancer	9.48e-05	0.001	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—CYP1A1—liver cancer	9.38e-05	0.000994	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	9.32e-05	0.000988	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	9.25e-05	0.00098	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—GGT1—liver cancer	8.57e-05	0.000908	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CPT1B—liver cancer	7.92e-05	0.000839	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GLUL—liver cancer	7.92e-05	0.000839	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—NR1H4—liver cancer	7.63e-05	0.000809	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTA3—liver cancer	7.51e-05	0.000795	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—UGDH—liver cancer	7.01e-05	0.000743	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	6.98e-05	0.000739	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTA4—liver cancer	6.86e-05	0.000727	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	6.71e-05	0.000711	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTA2—liver cancer	6.69e-05	0.000709	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—EPT1—liver cancer	6.59e-05	0.000699	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTA1—liver cancer	6.45e-05	0.000684	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CPT1B—liver cancer	6.44e-05	0.000683	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GLUL—liver cancer	6.44e-05	0.000683	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—NAT2—liver cancer	6.38e-05	0.000676	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—TAT—liver cancer	6.25e-05	0.000662	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—NR1H4—liver cancer	6.21e-05	0.000658	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.14e-05	0.00065	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ALDOB—liver cancer	6.12e-05	0.000648	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTA3—liver cancer	6.11e-05	0.000647	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CRABP1—liver cancer	5.84e-05	0.000618	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTA4—liver cancer	5.59e-05	0.000592	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	5.46e-05	0.000578	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTA2—liver cancer	5.44e-05	0.000577	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.25e-05	0.000557	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTA1—liver cancer	5.25e-05	0.000556	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—NAT2—liver cancer	5.19e-05	0.00055	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—HPGDS—liver cancer	5.1e-05	0.00054	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.07e-05	0.000537	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	4.99e-05	0.000529	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ALDOB—liver cancer	4.98e-05	0.000528	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CRABP1—liver cancer	4.75e-05	0.000503	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.62e-05	0.000489	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.56e-05	0.000483	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PSMD10—liver cancer	4.55e-05	0.000482	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PSMA4—liver cancer	4.55e-05	0.000482	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GOT2—liver cancer	4.42e-05	0.000469	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.28e-05	0.000453	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GLUL—liver cancer	4.25e-05	0.00045	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CPT1B—liver cancer	4.25e-05	0.00045	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CYP2E1—liver cancer	4.16e-05	0.000441	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—HPGDS—liver cancer	4.15e-05	0.00044	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.13e-05	0.000437	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—NR1H4—liver cancer	4.1e-05	0.000434	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTA3—liver cancer	4.03e-05	0.000427	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.03e-05	0.000427	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CYCS—liver cancer	3.89e-05	0.000412	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GOT1—liver cancer	3.82e-05	0.000405	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GGT1—liver cancer	3.82e-05	0.000405	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.76e-05	0.000398	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.71e-05	0.000393	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PSMA4—liver cancer	3.7e-05	0.000392	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PSMD10—liver cancer	3.7e-05	0.000392	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTA4—liver cancer	3.68e-05	0.00039	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GOT2—liver cancer	3.6e-05	0.000381	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTA2—liver cancer	3.59e-05	0.00038	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTA1—liver cancer	3.46e-05	0.000367	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTP1—liver cancer	3.43e-05	0.000363	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—NAT2—liver cancer	3.43e-05	0.000363	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CYP2E1—liver cancer	3.38e-05	0.000359	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—HMOX1—liver cancer	3.38e-05	0.000358	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ALDOB—liver cancer	3.28e-05	0.000348	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.28e-05	0.000347	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CYCS—liver cancer	3.17e-05	0.000336	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTM1—liver cancer	3.15e-05	0.000334	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CRABP1—liver cancer	3.13e-05	0.000332	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GOT1—liver cancer	3.11e-05	0.000329	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GGT1—liver cancer	3.11e-05	0.000329	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CYP1A1—liver cancer	2.99e-05	0.000317	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTP1—liver cancer	2.79e-05	0.000296	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—MTHFR—liver cancer	2.79e-05	0.000295	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—HMOX1—liver cancer	2.75e-05	0.000292	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—HPGDS—liver cancer	2.74e-05	0.00029	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PPARA—liver cancer	2.73e-05	0.00029	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTM1—liver cancer	2.57e-05	0.000272	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.45e-05	0.00026	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PSMA4—liver cancer	2.44e-05	0.000259	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PSMD10—liver cancer	2.44e-05	0.000259	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CYP1A1—liver cancer	2.43e-05	0.000258	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GOT2—liver cancer	2.37e-05	0.000252	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PIK3CG—liver cancer	2.34e-05	0.000248	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—MTHFR—liver cancer	2.27e-05	0.00024	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PPARG—liver cancer	2.26e-05	0.000239	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CYP2E1—liver cancer	2.23e-05	0.000236	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PPARA—liver cancer	2.22e-05	0.000236	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CYCS—liver cancer	2.09e-05	0.000221	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PIK3CD—liver cancer	2.06e-05	0.000218	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GOT1—liver cancer	2.05e-05	0.000217	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GGT1—liver cancer	2.05e-05	0.000217	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ALB—liver cancer	2.03e-05	0.000215	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2e-05	0.000212	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PIK3CG—liver cancer	1.9e-05	0.000202	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTP1—liver cancer	1.84e-05	0.000195	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PPARG—liver cancer	1.84e-05	0.000195	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—HMOX1—liver cancer	1.82e-05	0.000192	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PIK3CB—liver cancer	1.79e-05	0.00019	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTM1—liver cancer	1.69e-05	0.000179	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PIK3CD—liver cancer	1.67e-05	0.000177	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ALB—liver cancer	1.65e-05	0.000175	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CYP1A1—liver cancer	1.6e-05	0.00017	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—MTHFR—liver cancer	1.5e-05	0.000158	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PPARA—liver cancer	1.47e-05	0.000155	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PIK3CB—liver cancer	1.46e-05	0.000155	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PIK3CG—liver cancer	1.26e-05	0.000133	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PPARG—liver cancer	1.21e-05	0.000128	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PIK3CD—liver cancer	1.1e-05	0.000117	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PIK3CA—liver cancer	1.09e-05	0.000116	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ALB—liver cancer	1.09e-05	0.000115	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PIK3CB—liver cancer	9.63e-06	0.000102	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—AKT1—liver cancer	8.93e-06	9.46e-05	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PIK3CA—liver cancer	8.9e-06	9.43e-05	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—AKT1—liver cancer	7.27e-06	7.7e-05	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PIK3CA—liver cancer	5.87e-06	6.22e-05	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—AKT1—liver cancer	4.79e-06	5.08e-05	CbGpPWpGaD
